Fifth-generation cephalosporin (broad incl MRSA)

Ceftobiprole

Brand names: Mabelio, Zevtera

Ceftobiprole is a broad-spectrum parenteral cephalosporin antibacterial with anti-MRSA activity, used for hospital- and community-acquired pneumonia and, where licensed, certain other serious infections.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Its active form is a beta-lactam that binds penicillin-binding proteins, including PBP2a in MRSA, to inhibit cell-wall synthesis and produce a bactericidal effect.

Prescribing in practice

Avoid in patients with a history of immediate hypersensitivity to penicillins or other beta-lactams because of the risk of cross-reactivity.
Its broad spectrum including MRSA and many Gram-negative organisms means use should be reserved and guided by stewardship and susceptibility data.
Dose adjustment is required in renal impairment, in line with the SPC.

Monitoring

Monitor renal function and clinical response, and review therapy in line with microbiology advice during the course.

Counselling the patient

This antibiotic is given by infusion under clinical supervision.
Report any rash, swelling, breathing difficulty, or severe or persistent diarrhoea.

Evidence & guidelines

Ceftobiprole's efficacy in pneumonia and other serious infections was demonstrated in dedicated phase III trial programmes.

Reference: BSAC; UKHSA AMR; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Pathways